Mark Krakauer - Decision Diagnostics Head Efforts
| DECN Stock | USD 0.0001 0.00 0.00% |
Insider
Mark Krakauer is Head Efforts of Decision Diagnostics
| Address | 2660 Townsgate Road, Westlake Village, CA, United States, 91361 |
| Phone | 805 446 1973 |
| Web | https://www.decisiondiagnostics.co |
Decision Diagnostics Management Efficiency
The company has return on total asset (ROA) of (0.2122) % which means that it has lost $0.2122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (81.6052) %, meaning that it created substantial loss on money invested by shareholders. Decision Diagnostics' management efficiency ratios could be used to measure how well Decision Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 3rd of December 2024, Return On Tangible Assets is likely to grow to -8.02. In addition to that, Return On Capital Employed is likely to grow to -2.48. At this time, Decision Diagnostics' Other Current Assets are very stable compared to the past year. As of the 3rd of December 2024, Total Current Assets is likely to grow to about 2.5 M, while Total Assets are likely to drop about 5.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Justin McAnear | 10X Genomics | 48 | |
| Paul Jorgensen | Doximity | 53 | |
| Claus Jensen | Teladoc | N/A | |
| Jim Rivas | Doximity | N/A | |
| Courtney McLeod | Teladoc | N/A | |
| Shari Buck | Doximity | N/A | |
| Hemant Taneja | Teladoc | N/A | |
| Richard Napolitano | Teladoc | 57 | |
| George Brooks | Teladoc | N/A | |
| Rajeev Singh | Accolade | 56 | |
| Michael SchnallLevin | 10X Genomics | N/A | |
| Mike Waters | Teladoc | N/A | |
| Babak Azad | Goodrx Holdings | 51 | |
| Perry Gold | Doximity | N/A | |
| Glen Tullman | Teladoc | N/A | |
| Carolina Lobo | Accolade | N/A | |
| Vina Leite | Goodrx Holdings | 54 | |
| Tyson Murdock | HealthEquity | 53 | |
| Michael Sturmer | Progyny | 47 | |
| Mark Livingston | Progyny | 58 | |
| Ruth Backer | 10X Genomics | 47 | |
Management Performance
| Return On Equity | -81.61 | ||||
| Return On Asset | -0.21 |
Decision Diagnostics Management Team
Elected by the shareholders, the Decision Diagnostics' board of directors comprises two types of representatives: Decision Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Decision. The board's role is to monitor Decision Diagnostics' management team and ensure that shareholders' interests are well served. Decision Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Decision Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Krakauer, Head Efforts | ||
| Chris Knapp, Consultant | ||
| Keith Berman, CEO and President CFO, Principal Accounting Officer, Secretary, Treasurer and Director |
Decision Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Decision Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -81.61 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (0.95) % | ||||
| Current Valuation | 3.06 M | ||||
| Shares Outstanding | 357.87 M | ||||
| Price To Earning | (0.33) X | ||||
| Price To Book | 2.72 X | ||||
| Price To Sales | 0.02 X | ||||
| Revenue | 1.98 M | ||||
| Gross Profit | 194.17 K |
Pair Trading with Decision Diagnostics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Decision Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Decision Diagnostics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Decision Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Decision Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Decision Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Decision Diagnostics to buy it.
The correlation of Decision Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Decision Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Decision Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Decision Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Decision Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Decision Stock, please use our How to Invest in Decision Diagnostics guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Decision Diagnostics. If investors know Decision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Decision Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.02) | Revenue Per Share 0.006 | Quarterly Revenue Growth (0) | Return On Assets (0.21) | Return On Equity (81.61) |
The market value of Decision Diagnostics is measured differently than its book value, which is the value of Decision that is recorded on the company's balance sheet. Investors also form their own opinion of Decision Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Decision Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Decision Diagnostics' market value can be influenced by many factors that don't directly affect Decision Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Decision Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Decision Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Decision Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.